Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner

被引:91
作者
Kawasaki, Yuri
Kawagoe, Keiichi
Chen, Chun-jen
Teruya, Kenta
Sakasegawa, Yuji
Doh-ura, Katsurni
机构
[1] Tohoku Univ, Grad Sch Med, Dept Prion Res, Aoba Ku, Sendai, Miyagi 9808575, Japan
[2] Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, Tokyo, Japan
关键词
D O I
10.1128/JVI.01563-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The establishment of effective therapeutic interventions for prion diseases is necessary. We report on a newly developed amyloidophilic compound that displays therapeutic efficacy when administered orally. This compound inhibited abnormal prion protein formation in prion-infected neuroblastoma cells in a prion strain-dependent manner: effectively for RML prion and marginally for 22L prion and Fukuoka-1 prion. When the highest dose (0.2% [wt/wt] in feed) was given orally to cerebrally RML prion-inoculated mice from inoculation until the terminal stage of disease, it extended the incubation periods by 2.3 times compared to the control. The compound exerted therapeutic efficacy in a prion strain-dependent manner such as that observed in the cell culture study: most effective for RML prion, less effective for 22L prion or Fukuoka-1 prion, and marginally effective for 263K prion. Its effectiveness depended on an earlier start of administration. The glycoform pattern of the abnormal prion protein in the treated mice was modified and showed predominance of the diglycosylated form, which resembled that of 263K prion, suggesting that cliglycosylated forms of abnormal prion protein might be least sensitive or resistant to the compound. The mechanism of the prion strain-dependent effectiveness needs to be elucidated and managed. Nevertheless, the identification of an orally available amyloidophilic chemical encourages the pursuit of chemotherapy for prion diseases.
引用
收藏
页码:12889 / 12898
页数:10
相关论文
共 32 条
[1]   Probing the dynamics of prion diseases with amphotericin B [J].
Adjou, KT ;
Deslys, JP ;
Demaimay, R ;
Dormont, D .
TRENDS IN MICROBIOLOGY, 1997, 5 (01) :27-31
[2]  
Bresjanac M, 2003, J NEUROSCI, V23, P8029
[3]   Radioligand development for PET imaging of β-amyloid (AD)-current status [J].
Cai, Lisheng ;
Innis, Robert B. ;
Pike, Victor W. .
CURRENT MEDICINAL CHEMISTRY, 2007, 14 (01) :19-52
[4]   Prion diseases - Close to effective therapy? [J].
Cashman, NR ;
Caughey, B .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (10) :874-884
[5]   POTENT INHIBITION OF SCRAPIE-ASSOCIATED PRP ACCUMULATION BY CONGO RED [J].
CAUGHEY, B ;
RACE, RE .
JOURNAL OF NEUROCHEMISTRY, 1992, 59 (02) :768-771
[6]   SULFATED POLYANION INHIBITION OF SCRAPIE-ASSOCIATED PRP ACCUMULATION IN CULTURED-CELLS [J].
CAUGHEY, B ;
RAYMOND, GJ .
JOURNAL OF VIROLOGY, 1993, 67 (02) :643-650
[7]   Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation [J].
Doh-Ura, K ;
Iwaki, T ;
Caughey, B .
JOURNAL OF VIROLOGY, 2000, 74 (10) :4894-4897
[8]   Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models [J].
Doh-Ura, K ;
Ishikawa, K ;
Murakami-Kubo, I ;
Sasaki, K ;
Mohri, S ;
Race, R ;
Iwaki, T .
JOURNAL OF VIROLOGY, 2004, 78 (10) :4999-5006
[9]   Enhanced CD9 expression in the mouse and human brains infected with transmissible spongiform encephalopathies [J].
Doh-ura, K ;
Mekada, E ;
Ogomori, K ;
Iwaki, T .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2000, 59 (09) :774-785
[10]   Prophylactic effect of dietary seaweed fucoidan against enteral prion infection [J].
Doh-ura, Katsumi ;
Kuge, Tomoko ;
Uomoto, Miyuki ;
Nishizawa, Keiko ;
Kawasaki, Yuri ;
Iha, Masahiko .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (06) :2274-2277